Clin Exp Pediatr.  2023 Sep;66(9):384-394. 10.3345/cep.2022.01032.

Treatment of congenital cytomegalovirus infection

• Shim GH

• KMID: 2545402
• DOI: http://doi.org/10.3345/cep.2022.01032

Abstract

Congenital cytomegalovirus (CMV) is the most common cause of congenital infection worldwide, the most common nongenetic cause of sensorineural hearing loss in children, and a cause of neurodevelopmental disorders in the brain. Infants with symptomatic congenital CMV infection may benefit from hearing and neurodevelopmental outcomes, particularly if antiviral treatment is initiated within the first month of life. Infants with life-threatening symptoms are recommended to receive 2–6 weeks of intravenous ganciclovir and then switch to oral valganciclovir, and those without life-threatening symptoms are recommended to use oral valganciclovir during the entire 6-month period. During antiviral drug treatment, absolute neutrophil count, platelet count, blood urea nitrogen, creatinine, and liver function tests were performed to identify neutropenia, thrombocytopenia, renal failure, and liver failure. This review investigated the evidence to date of treating congenital CMV infection.

Keyword

Congenital; Cytomegalovirus infections; Ganciclovir; Valganciclovir; Sensorineural hearing loss